Trial Profile
Effect of the DPP-4 inhibitor, saxagliptin on glucose variability in type 2 diabetes patients with Chronic kidney disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 14 Jun 2018 Status changed from recruiting to discontinued.
- 04 Apr 2017 New trial record